Assessment of Serum Pepsinogens with and without Co-Testing with Gastrin-17 in Gastric Cancer Risk Assessment—Results from the GISTAR Pilot Study

Introduction––Serum pepsinogen tests for gastric cancer screening have been debated for decades. We assessed the performance of two pepsinogen assays with or without gastrin-17 for the detection of different precancerous lesions alone or as a composite endpoint in a Latvian cohort. Methods––Within t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Claudia Robles, Dace Rudzite, Inese Polaka, Olga Sjomina, Lilian Tzivian, Ilze Kikuste, Ivars Tolmanis, Aigars Vanags, Sergejs Isajevs, Inta Liepniece-Karele, Danute Razuka-Ebela, Sergej Parshutin, Raul Murillo, Rolando Herrero, Jin Young Park, Marcis Leja
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-07-01
Edice:	Diagnostics
Témata:	serum pepsinogens gastrin-17 gastric cancer prevention screening public health
On-line přístup:	https://www.mdpi.com/2075-4418/12/7/1746
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!